Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — H1 2025 Earnings Presentation

21 slides from Vivoryon Therapeutics's earnings presentation, Sep 4, 2025

  1. Slide 1: Half Year 2025: Financial Results & Operational Update

    Half Year 2025: Financial Results & Operational Update September 4, 2025 Vivoryon Therapeutics N.V.

  2. Slide 2: Agenda

    Agenda Recent Key Achievements Julia Neugebauer, PhD Chief Operating Officer Financial Results Anne Doering, CFA Chief Financial Officer Q&A Targeting QPCTL in Kidney Disease Michael Schaeffer, PhD Chief Business Officer Advancing Strategic Priorities Frank Weber, MD Chief Executive Officer © Vivory

  3. Slide 3: Important notice and disclaimer

    Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment

  4. Slide 4: Recent Key Achievements

    Recent Key Achievements Julia Neugebauer, PhD COO

  5. Slide 5: Vivoryon's approach and expertise positions company for future growth

    Vivoryon’s approach and expertise positions company for future growth and supports development of innovative oral therapies for kidney disease and beyond ◆ Chronic Kidney Disease (CKD) is a rising global health problem and is set to become the fifth leading cause of years of life lost by 20401 ◆ CKD

  6. Slide 6: Varoglutamstat in DKD/CKD: Continuing to build robust body of evidence

    Varoglutamstat in DKD/CKD: Continuing to build robust body of evidence advancing kidney disease program H1 2025 Achievements Building evidence & 2024 Phase 2b DKD preparations 2023 ◆ Compelling kidney function data & meta-analysis from two Ph 2 studies - oral presentation at ERA Data-driven shift to

  7. Slide 7: H1 2025 Financial Results

    H1 2025 Financial Results Anne Doering, CFA CFO

  8. Slide 8: Key financial figures and corporate update

    Key financial figures and corporate update In €k Six months ended Six months ended Jun 30, 2025 Jun 30, 2024 Revenue 0 0 Research & Development expenses (2,768) (10,308) General & Administrative expenses (2,755) (3,501) Net loss for the period (5,473) (13,559) In €k Jun 30, 2025 Dec 31, 2024 Cash &

  9. Slide 9: Targeting QPCTL in Kidney Disease

    Targeting QPCTL in Kidney Disease Michael Schaeffer, PhD CBO

  10. Slide 10: Varoglutamstat's target QPCTL plays a crucial role in protein maturation and inflammation

    Varoglutamstat’s target QPCTL plays a crucial role in protein maturation and inflammation Chronic kidney tissue damage can lead to higher expression of QPCTL which can accelerate inflammation and organ fibrosis, organ dysfunction and finally kidney failure 1. Peptides including pro-inflammatory chem

  11. Slide 11: Varoglutamstat effectively reduces pro-inflammatory cytokines pE-CCL2 and pE-CCL13

    Varoglutamstat effectively reduces pro-inflammatory cytokines pE-CCL2 and pE-CCL13 in plasma ◆ Measurement of VIVIAD plasma samples1 using new, highly sensitive, liquid chromatography- mass spectrometry (LC/MS)-based assay revealed a reduction in pE-CCL2 and pE-CCL13 levels ◆ Statistically significa

  12. Slide 12: Dose-dependent reduction of pE-CCL2 correlates with improvement of eGFR

    Dose-dependent reduction of pE-CCL2 correlates with improvement of eGFR Median reduction in pE-CCL2 levels at week 48 Varoglutamstat effect on kidney function outcomes compared to baseline with varoglutamstat (total population; change in eGFR over time slope analysis (total population) (MDRD)1) 1 Ch

  13. Slide 13: Improvement of eGFR correlates with reduction of pE-CCL2 on individual patient level

    Improvement of eGFR correlates with reduction of pE-CCL2 on individual patient level, in line with total population data Varoglutamstat treatment decreases pE-CCL2 in majority of participants Statistically significant correlation between change in pE-CCL2 serum levels at week 48 and the slope in eGF

  14. Slide 14: New diabetic kidney disease preclinical model results corroborate effects of varoglutamstat

    New diabetic kidney disease preclinical model results corroborate effects of varoglutamstat on inflammation, fibrosis and kidney function 0.50 (% fractional area) Inflammation 0.40 Kidney CD11c 0.30 ◆ Evaluated varoglutamstat in an established preclinical model 0.20 ** specific for DKD (reninAAV-acc

  15. Slide 15: Varoglutamstat reduces oxidative stress in Fabry disease kidney cells

    Varoglutamstat reduces oxidative stress in Fabry disease kidney cells About Fabry disease ◆ Rare genetic disorder affecting more than 1/15,000 people1, resulting from a deficiency of the enzyme alpha-galactosidase A ◆ Leads to accumulation of certain metabolic products inside cells of the kidney (po

  16. Slide 16: Advancing Strategic Priorities

    Advancing Strategic Priorities Frank Weber, MD CEO

  17. Slide 17: Varoglutamstat: Potential to become a convenient new oral therapy

    Varoglutamstat: Potential to become a convenient new oral therapy to transform the treatment of kidney disease Medical Need Opportunity Therapies that can stabilize Varoglutamstat is a first-in-class single agent oral compound that has or improve kidney function been shown to stabilize and partially

  18. Slide 18: Where we are today

    Where we are today ◆ Strong proof of concept that varoglutamstat increases eGFR and improves kidney function ◆ Strong evidence supporting MoA: inhibition of intracellular QPCTL reduces amount of Compelling Body activated potent pyroglutamylated pro-inflammatory and pro-fibrotic peptides of Evidence

  19. Slide 19: Advancing Strategic Priorities

    Advancing Strategic Priorities Financing/Partnership Phase 2b Preparations ◆ New study requires additional funds ◆ In final steps to select CRO for planned Phase 2b DKD study ◆ Actively pursuing financing and partnership opportunities in parallel ◆ Activities ongoing aimed at minimizing time/cost to

  20. Slide 20: Q&A

    Q&A

  21. Slide 21: Vivoryon Therapeutics N.V.

    Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com

Vivoryon Therapeutics — H1 2025 Earnings Presentation on 6ix